Skip to content
HowShorted

Iovance Biotherapeutics, Inc. short interest in 2023

In 2023, Iovance Biotherapeutics, Inc.'s disclosed short interest ran from 12.74% of shares outstanding on 13 Jan 2023 to 14.23% on 29 Dec 2023, a change of +1.49 percentage points. The year's high was 15.88% on 31 Mar 2023 and its low 9.65% on 31 May 2023, averaging 13.15% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.15 days on 28 Apr 2023. Full history: Iovance Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Iovance Biotherapeutics, Inc. in 2023

2023 in figures

Start of year
12.74% (13 Jan 2023)
End of year
14.23% (29 Dec 2023)
Change
+1.49 pp
High
15.88% (31 Mar 2023)
Low
9.65% (31 May 2023)
Average
13.15%
Highest days to cover
9.15 (28 Apr 2023)
SEC filings marked
9

Every report in 2023

Iovance Biotherapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202312.74%6.33
31 Jan 202313.11%3.02
15 Feb 202312.55%6.07
28 Feb 202312.25%6.3110-K filed, results (8-K)
15 Mar 202314.32%6.40
31 Mar 202315.88%6.12
14 Apr 202314.71%6.70
28 Apr 202315.13%9.15
15 May 202310.42%4.66results (8-K), 10-Q filed
31 May 20239.65%2.53
15 Jun 202311.42%4.38
30 Jun 202312.87%5.14
14 Jul 202311.57%3.48results (8-K)
31 Jul 202312.27%6.83
15 Aug 202311.11%5.9110-Q filed, results (8-K)
31 Aug 202312.14%7.98
15 Sep 202312.31%2.99
29 Sep 202314.84%4.57
13 Oct 202315.64%7.40
31 Oct 202315.19%7.01
15 Nov 202313.91%5.7910-Q filed, results (8-K)
30 Nov 202313.52%4.14
15 Dec 202313.78%4.60
29 Dec 202314.23%3.19

See also: Iovance Biotherapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.